eClinical Technology and Industy News

GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,” in the peer-reviewed journal mAbs.

The article demonstrates the potential of GigaGen’s machine learning platform to improve the discovery and development of therapeutic antibodies. GigaGen’s machine learning models predict and generate sequences of antibodies that best bind to specific targets and can be used to later generate novel recombinant antibodies against those targets for potential therapeutic application.

Carter Keller, chief executive officer at GigaGen, commented, “This research demonstrates how GigaGen’s machine learning methods can be leveraged to mine and learn patterns in antibody sequences, offering further insights into antibody engineering, optimization and discovery. While the article focuses on two main oncology targets, PD-1 and CTLA-4, the potential application of our technology is widespread to multiple disease targets, and we are excited to continue exploring its applicability in the future.”

About Grifols
Grifols is a global company in the health sector that has been working since 1909 to improve the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services in more than 110 countries.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?